Investigational once-weekly GLP-1 and amylin receptor agonist achieves up to 14.6% weight loss and significant blood sugar reductions
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
The standout story remains Wegovy, particularly its new oral formulation
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
Subscribe To Our Newsletter & Stay Updated
